Before 2017, drug companies will suffer patent losses of $140 billion.
Reuters, May 1, 2007
Now is the time for pharmaceutical companies – both brand name and generic – to rethink patent strategies not only in terms of this impending economic reality, but also in terms of the dramatic changes to the patent landscape on every front – in Congress, at the PTO, and in the courts.
American Conference Institute’s 9th Annual Maximizing Pharmaceutical Patent Life Cycles will be held October 15-16, 2008, in New York, NY.
Patent counsel and advisors to leading pharmaceutical companies, as well as representatives from key government agencies will provide insights on the latest Hatch-Waxman challenges and bring you the latest legal strategies and tactics for successful maneuvering in the revised patent endgame. With all that’s at stake, you cannot afford to miss this conference.
Related posts:
- Maximizing Pharmaceutical Patent Lifecycles The Americ
- Upcoming Patent Events: Pharmaceutical and Biotech Patent Opinion Writing Billed as
- Pharmaceutical Patent Law: A Prescription for Success in Challenging Times BNA, the l
- Upcoming Patent Events: Business Methods Patents The busine
- Upcoming Patent Events: Pharma/Biotech IP Due Diligence Whether yo
Related posts brought to you by Yet Another Related Posts Plugin.
